Education
About Us
Working with TipRanks
Follow Us
CVRx (CVRX)
NASDAQ:CVRX
CVRX Stock Chart & Stats
$8.22
-$0.03(-0.21%)
At close: 4:00 PM EST
$8.22
-$0.03(-0.21%)
Day’s Range― - ―
52-Week Range$4.30 - $13.34
Previous CloseN/A
Volume20.10K
Average Volume (3M)197.28K
Market Cap
$216.28M
Enterprise Value$189.61M
Total Cash (Recent Filing)$75.71M
Total Debt (Recent Filing)$50.79M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Apr 29, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding26,311,607
10 Day Avg. Volume162,574
30 Day Avg. Volume197,283
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)4.71
Price to Sales (P/S)3.27
P/FCF Ratio-4.54
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue3.35
Enterprise Value/Gross Profit3.92
Enterprise Value/Ebitda-3.98
Forecast
1Y Price Target
$11.00Price Target Upside33.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.95
Revenue Forecast (FY)$64.72M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ExpansionCMS Category B coverage and initiation of the BENEFIT-HF randomized trial could materially expand the addressable market for Barostim by raising awareness among cardiology specialists and increasing procedure volumes if the study demonstrates clinical benefit.
Financial Performance And Guidance AlignmentReported quarterly results that exceeded expectations and management revenue guidance that aligns with analyst estimates indicate improving utilization and accelerating business momentum, which could support upside to forecasts.
Reimbursement ImprovementImplementation of Category I CPT codes combined with potential public payer coverage for trial participants is likely to reduce reimbursement friction and improve commercial access for Barostim, supporting broader adoption.
Bears Say
Increased Leverage And Cash RiskAmendment and draw on the term loan facility increased leverage and extended an interest-only period under relatively high interest terms, elevating financial risk and investor concern about the company's cash position.
Net Account Addition ShortfallSunsetting lower-utilizing centers produced net account additions below expectations, a shortfall that may harm perceptions of growth and weigh on investor sentiment despite being part of strategic account rationalization.
Salesforce Reorganization DisruptionSalesforce reorganization has disrupted accounts and left representatives below expected productivity, which may hinder expansion into new centers and slow commercial execution.
CVRx News
CVRX FAQ
What was CVRx’s price range in the past 12 months?
CVRx lowest stock price was $4.30 and its highest was $13.34 in the past 12 months.
What is CVRx’s market cap?
CVRx’s market cap is $216.28M.
When is CVRx’s upcoming earnings report date?
CVRx’s upcoming earnings report date is Apr 29, 2026 which is in 56 days.
How were CVRx’s earnings last quarter?
CVRx released its earnings results on Feb 12, 2026. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.439 by -$0.021.
Is CVRx overvalued?
According to Wall Street analysts CVRx’s price is currently Undervalued.
Does CVRx pay dividends?
CVRx does not currently pay dividends.
What is CVRx’s EPS estimate?
CVRx’s EPS estimate is -0.52.
How many shares outstanding does CVRx have?
CVRx has 26,311,607 shares outstanding.
What happened to CVRx’s price movement after its last earnings report?
CVRx reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.439. Following the earnings report the stock price went down -13.005%.
Which hedge fund is a major shareholder of CVRx?
Currently, no hedge funds are holding shares in CVRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CVRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (33.82% Upside)
$11.00 (33.82% Upside)
Blogger Sentiment
Bullish
CVRX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 5.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $183.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.42%
12-Months-Change
Fundamentals
Return on Equity
-91.88%
Trailing 12-Months
Asset Growth
-12.80%
Trailing 12-Months
Company Description
CVRx
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
CVRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights important commercial and reimbursement milestones (Category I CPT code, improved prior authorization rates), stronger gross margins and a major clinical trial (BENEFIT HF) that can materially expand the addressable market long-term. These positives are balanced against continued net losses, sizable and growing operating expense guidance, expected cash burn in 2026, and near-term revenue growth that remains modest as a larger sales organization continues to ramp. Management emphasizes building durable programs and long-term growth rather than short-term profitability.View all CVRX earnings summariesCVRX Stock 12 Month Forecast
Average Price Target
$11.00
▲(33.82% Upside)
Technical Analysis
Ownership Overview
26.97% Insiders
6.58% Mutual Funds
19.77% Other Institutional Investors
40.51% Public Companies and
Individual Investors